Get instant access to our resource bundle and learn how others are using Mitra® devices with VAMS® technology and remote specimen collection to study SARS-CoV-2, influenza, and other infectious diseases, and the drugs that treat them.
Download Now
Our Infectious Disease Resource Bundle will help you easily adopt a new, remote approach to sample collection that enables research studies and clinical trials to occur at-home, in the field, or in locations without clinically trained staff. Mitra® devices with VAMS® technology provide simple precision for remote microsampling and efficient, automated lab processing. Learn how the National Institutes of Health (NIH), Swiss Tropical Institute, LGC Group, and other organizations are deploying remote microsampling with Mitra® devices globally.
Source/Credit: NIBIB/NIH. Nature Communications. Volume 12, Article number: 113 (2021)
Mitra® remote microsampling devices are extremely well-suited for both small and large-scale serology studies. Research provided in our resource bundle illustrates:
Access our Resource Bundle for all these details plus insight into a multiplex assay that uses Mitra devices to simultaneously measure >30 strains of influenza.
Credit: Christopher Barnes and Pamela Bjorkman, California Institute of Technology, Pasadena.
Accurate measurement of antibody levels is critical for understanding both natural and vaccine-induced immunity. Antibody and immunity studies will inform "immunity passports," facilitating a return to school, work, and other activities. These studies benefit from remote microsampling. Mitra microsamples are quantitative and precise (RSD < 4%), enabling the reporting of specific titer levels. Data within our resource bundle shows:
Read all about this data and more in our Infectious Disease Research Resource Bundle and access the relevant literature for more insights.
Credit: DropBio Pty Ltd (data provided as a courtesy prior to publication)
Researchers investigate cytokines and other biomarkers as early predictors of severe Covid-19 illness. They are hopeful at the prospect of earlier identification and intervention of patients at high risk for severe Covid-19 and other infections. Data included in our Resource Bundle illustrates that the following is possible with Mitra devices:
Learn more by reading our news articles, including the one titled, cytokines as predictive biomarkers of severe COVID-19: could at-home sampling be helpful?
Collecting biological specimens in low-resource areas to study tropical diseases is difficult and expensive. Mitra devices offer a convenient, reliable, and cost-effective solution to these issues. Mitra devices with VAMS tips also overcome the drying and analytical bias issues encountered with dried blood spot cards. Leading research institutions specializing in tropical medicine prefer Mitra collection for a variety of research projects, such as:
Read our Infectious Disease Resource Bundle for additional insights on how to implement remote MItra microsampling in tropical medicine.
As the Coronavirus Pandemic spread around the globe in 2020, we saw accelerated adoption of Mitra® devices and VAMS® technology for remote microsampling studies. With entire countries in lockdown, researchers realized it was time to fully embrace remote studies, decentralized trials, and virtual models. You can offer remote specimen collection to help people avoid exposure to contagions while they contribute to science.
Leaders in infectious disease research use microsampling in innovative ways, from remote vaccine studies to drug trials for effective therapies.
Mitra devices with VAMS technology deliver on the promise of microsampling with simplicity and precision ... Start your volumetric microsampling study today!
The strong correlation between anti-RBD IgG and mAbs, combined with the demonstration in this study and by others that anti-RBD can reliably be measured from dried blood finger-prick samples, provides feasibility for future SARS-CoV-2 immunokinetic studies that incorporate RBD-IgG-based assays.”
— Alana Whitcombe, PhD candidate & scientist, Auckland University, New Zealand
The NIH ELISA-based serology protocol using Mitra® microsampling devices with VAMS® technology from Neoteryx gives all scientists a reliable method for identifying SARS-CoV-2 raised antibodies in blood microsamples with amazing specificity, which is critical during the coronavirus pandemic.”
— James Rudge, PhD, Technical Director, Neoteryx, USA
Our COVID-19 assay is suitable for partnering with employers for back to work testing using the self-sampling Mitra® device, and therefore does not require a phlebotomist to take the blood sample in a healthcare setting.”
– Michael van der Merwe, Commercial Director, LGC, United Kingdom
Researchers have considerable experience using these at-home blood collection kits to track the spread of other infectious diseases like influenza, and this method is safe, effective and easy-to-use. With a small finger-prick, volunteers can help scientists fight COVID-19 from their homes."
– Kaitlyn Sadtler, PhD, Study Lead and Section Chief, Immunoengineering at NIBIB, National Institutes of Heath (NIH)
"[During the pandemic] we haven't been able to collect samples in person for our studies, so remote microsampling has enabled us to run studies when we were otherwise shut down. It also enables us to collect longitudinal samples from a large number of subjects across a range of geographies."
– Dr. Michael Snyder, The Snyder Lab, Stanford Medicine
Safer, Simpler, Smarter, and More Convenient.
421 Amapola Ave
Torrance, CA 90501
Call us: 1 (310) 787-8747
info@neoteryx.com
Mitra® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.
Copyright © 2022 Neoteryx, LLC, Part of the Trajan Family. All rights reserved.